epicur
MARCH 12, 2024
Epicur Pharma’s Advisory Council member Ann Donoghue, DVM, MS shares her personal perspective on the important relationship between veterinary oncology and compounded medications used in chemotherapy treatments. Many of the presentations discussed the chemotherapies available to treat dogs.
European Pharmaceutical Review
DECEMBER 5, 2022
PSMAfore, is a Phase III, open-label, multi-centre, 1:1 randomised study comparing the efficacy and safety of Pluvicto to a change in ARPI in 469 patients with PSMA–positive mCRPC. Pluvicto is an intravenous radioligand therapy that combines a ligand, a targeting compound with lutetium-177, a therapeutic radionuclide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
epicur
SEPTEMBER 13, 2023
However, the more closely we look at what it takes to compound an exact strength, the clearer it becomes standard dosages are more beneficial to both patients and veterinary practices. Exact strengths are compounded by a technician in capsules or tablets at traditional 503A pharmacies. milligram tablet and a 1.6 milligram tablet.
European Pharmaceutical Review
JULY 5, 2022
The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.
pharmaphorum
DECEMBER 5, 2022
Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.
European Pharmaceutical Review
AUGUST 17, 2022
Radioligand therapy (RLT), which combines a targeting compound (ligand) with a therapeutic radioactive atom (radioisotope), is an emerging treatment approach that may offer an alternative treatment option for some cancer patients. Its licensing makes it the first diagnostic PSMA imaging tracer to receive this status in Great Britain.
pharmaphorum
APRIL 20, 2021
One of the filings is to convert the ADC’s current conditional approval as a later-line therapy for urothelial cancer in patients previously treated with PD-1/L1 checkpoint inhibitors and platinum-based chemotherapy into a full approval. Both have been granted an FDA priority review with an action date of 17 August.
Expert insights. Personalized for you.
52 
Let's personalize your content